Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge

JAMA Oncol. 2020 Nov 1;6(11):1813-1814. doi: 10.1001/jamaoncol.2020.3955.

Authors

Jie Liu¹, Jinming Yu¹, Xue Meng¹

Affiliation

¹ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

PMID: 32970130
DOI: 10.1001/jamaoncol.2020.3955

No abstract available

Publication types

Letter
Comment

MeSH terms

Drug-Related Side Effects and Adverse Reactions*
Humans
Immune Checkpoint Inhibitors / adverse effects
Immune System Diseases*
Neoplasms* / drug therapy
Neoplasms* / immunology

Substances

Immune Checkpoint Inhibitors